Sodium-glucose cotransporter inhibitors: Beyond glycaemic control

Clinical Kidney Journal

Volumn 12, Issue 3, 2019, Pages 322-325

  Vergara, Ander ^a,b   Jacobs Cachá, Conxita ^a,b   Soler, María José ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chronic kidney disease; Diabetic nephropathy; SGLT2; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER INHIBITOR;

BLOOD PRESSURE REGULATION; BODY WEIGHT LOSS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HUMAN; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW;

EID: 85071188294     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfz019     Document Type: Review

References (33)

1. Xie Y, Bowe B, Mokdad AH et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from1990 to 2016. Kidney Int 2018; 94: 567-581
2. Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
3. Palazzolo G, Albanese NN, DI Cara G et al. Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res 2012; 32: 847-860
4. Gerstein HC, Miller ME, Byington RP et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
5. UPDS Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
6. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
8. Mann JFE, Anderson C, Gao P et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes. J Hypertens 2013; 31: 414-421
9. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
10. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
11. Heerspink HJL, Desai M, Jardine M et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28: 368-375
12. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017; 13: 11-26
13. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457-466
14. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
15. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
16. Perkovic V, de Zeeuw D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6: 691-704
17. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2018; 46: 462-472
18. Satirapoj B, Korkiatpitak P, Supasyndh O. Effect of SGLT-2 inhibitor to proximal tubular function and injury in 2 patients with type 2 diabetes: a randomized controlled trial. Clin Kidney J 2019
19. Dekkers CCJ, Petrykiv S, Laverman GD et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20: 1988-1993
20. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11: 749-761
21. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555
22. Shin SJ, Chung S, Kim SJ et al. Effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on renal reninangiotensin system in an animal model of type 2 diabetes. PLoS One 2016; 11: e0165703
23. Ye Y, Bajaj M, Yang H-C et al. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 2017; 31: 119-132
24. Tahara A, Takasu T. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur J Pharmacol 2018; 830: 68-75
25. Leng W, Ouyang X, Lei X et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE -/- mice. Mediators Inflamm 2016; 2016: 1-13
26. Ma Q, Steiger S, Anders H-J. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep 2017; 5: e13228
27. Zhang Y, Thai K, Kepecs DM et al. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One 2016; 11: e0144640
28. Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013; 8: e54442
29. Zhang Y, Nakano D, Guan Y et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 2018; 94: 524-535
30. Abbas NAT, El Salem A, Awad MM. Empagliflozin, SGL T2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. Naunyn Schmiedebergs Arch Pharmacol 2018; 39: 1347-1360
31. Cassis P, Locatelli M, Cerullo D et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight 2018; 3: pii: 98720
32. Kitada K, Nakano D, Ohsaki H et al. Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complications 2014; 28: 604-611
33. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 2015; 48: 191-195